Credit Suisse Ag Editas Medicine, Inc. Put Options Transaction History

Credit Suisse Ag

4 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $1.12 Million - $1.71 Million	-42,100 Reduced 86.98%	6,300 $167,000
Q3 2021 Nov 12, 2021	SELL	$39.27 - $72.94 $3.42 Million - $6.36 Million	-87,200 Reduced 64.31%	48,400 $1.99 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $1.51 Million - $2.73 Million	48,200 Added 55.15%	135,600 $7.68 Million
Q1 2021 May 14, 2021	BUY	$39.71 - $90.58 $3.47 Million - $7.92 Million	87,400 New	87,400 $3.67 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $98.3M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.